Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $270.48M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.69M
Average 3.81M
ALT Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Altimmune, Inc.NASDAQ: ALT
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $22.56M (cash outflow) rose 15.3% year over year, ahead of the +0.9% change in trailing-twelve-month net income. Sequentially, it fell 17.5% from the prior quarter. Over 3 fiscal years it compounded at +1.3% a year.
Context
- Net income amounted to 214861.0% of revenue in FY2025, down 260434.0 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$54.33M (-38.3%) for the fiscal year ending Dec 2026, a slowdown from the -7.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$22.56M-17.5% QoQ
- Last fiscal yearDec 2025
- -$88.09M-7.3% YoY
- LTMMar 2026
- -$91.08M+0.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +15.3% | +28.4% | +13.1 pp |
| 1 year | -7.3% | -38.3% | -31.0 pp |
| 3-year CAGR | +1.3% | -10.0% | -11.3 pp |
| 5-year CAGR | -5.2% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (88.09M) USD
- Year-over-year change
- +7.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (88.09M) | +7.3% |
| FY2024 | 2024-12-31 | (95.06M) | -7.5% |
| FY2023 | 2023-12-31 | (88.45M) | -4.4% |
| FY2022 | 2022-12-31 | (84.71M) | +12.7% |
| FY2021 | 2021-12-31 | (97.09M) | — |
Net Income vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.9% is the 5th highest of 9, against a peer median of -1.8%.
- Net income amounts to 253002.8% of revenue for ALT, versus a peer median of 89.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $442.72M USD | -23.4% | — | 676.0% | |
| FY2025 | €340.16M EUR | +84.7% | +84.4% | 7587.8% | |
| LTM Jun 2026 | $291.03M USD | +62.6% | +40.1% | — | |
| LTM Mar 2026 | $160.72M USD | +309.9% | -21.6% | 84.0% | |
| LTM Mar 2026 | $91.08M USD | +0.9% | +1.3% | 253002.8% | |
| LTM Mar 2026 | $61.98M USD | -35.7% | -12.4% | 89.6% | |
| LTM Mar 2026 | $44.95M USD | -65.1% | -8.9% | — | |
| LTM Mar 2026 | $18.86M USD | +19.7% | +13.3% | — | |
| LTM Mar 2026 | $6.38M USD | -84.0% | -59.6% | 9.0% | |
| Peer median (excluding ALT) | — | -1.8% | -8.9% | 89.6% | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (681K) |
| Stock-Based Compensation | 5.52M | 8.1M | 10.64M | 14.39M | 16.08M |
| Change in Working Capital | (251K) | 14.11M | (8.27M) | 4.48M | 6.75M |
| Accounts Receivables | 6.53M | 3.3M | (2.31M) | 1.74M | 2.06M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.42M | 2.77M | (2.73M) | (1.86M) | 2.51M |
| Other Working Capital | (8.21M) | 8.04M | (3.23M) | 4.6M | 2.19M |
| Other Non-Cash Items | 13.03M | (578K) | 9.79M | (3.9M) | (1.7M) |
| Operating Cash Flow | (78.24M) | (62.59M) | (75.81M) | (79.85M) | (67.54M) |
| Capital Expenditures | (12.31M) | (126K) | (47K) | 0 | (11K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.59M) | (73.27M) | (88.63M) | (115.73M) | (285.45M) |
| Sales of Investments | 107.43M | 0 | 102.41M | 87.35M | 152.99M |
| Other Investing Activities | (195K) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 87.52M | (73.4M) | 13.73M | (28.39M) | (132.47M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 33.92M |
| Common Stock Issued | 65.04M | 56.35M | 86.6M | 9.99M | 173.73M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 58K | 434K | (496K) | 50K | (709K) |
| Financing Cash Flow | 65.1M | 56.78M | 86.11M | 10.04M | 206.84M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 74.38M | (79.2M) | 24.03M | (98.19M) | 6.83M |
| Free Cash Flow | (90.55M) | (62.71M) | (75.86M) | (79.85M) | (67.55M) |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.